Literature DB >> 26873529

Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.

Karolina M Stepien1, Christian J Hendriksz2, Mark Roberts3, Reena Sharma4.   

Abstract

Pompe disease is an autosomal recessive disease resulting from deficiency of the acid alpha-glucosidase (GAA). The late-onset Pompe Disease (LOPD) patients develop muscular and respiratory complications later in life. We describe a retrospective observational cohort study including 22 patients with LOPD. The cohort was assessed at baseline before Enzyme Replacement Therapy (ERT) with alglucosidase alpha (20mg/kg biweekly) was commenced and subsequently relevant information was collected at 2, 4 and 5years later. The median age of the patients at study entry was 44years (16-64years), with median disease duration of 11.5years (4-31years). At baseline, 10 patients (45%) could walk without support, 12 (55%) could walk with unilateral or bilateral support including 3/12 were wheelchair bound. Mean predicted FVC % was 55.7 (95% CI 45-66) of predicted normal at baseline and showed no significant change after 5years (54.6 (95% CI 43-66)), (all p=0.9815). Mean FVC % supine was 41.8 (95% CI 33.8-49) of predicted normal at baseline and remained significantly unchanged at 5years (48.4 (95% CI 37-59.6)), (all p=0.8680). The overnight non-invasive ventilator dependence increased by 18.2% as compared with baseline and requirement of mobility aids increased during this period by 5.2% as compared with the baseline. Mean walking distance at 6min walk test was 411.5 (95% CI 338-485) at baseline, 266.5 (95% CI 187-346) m at 2years, 238.6 (95% CI 162-315) m at 4years and 286.8 (95% CI 203-370) m at 5years (p=0.1981; ANOVA was completed only for 14 patients). A gradual decline in FVC% predicted was noted only in four cases and a decline in FVC% supine in two other. Only one patient showed a decline in both pulmonary function tests. In all remaining cases (17/22) respiratory function remains stable. In conclusion overall pulmonary function tests and mobility remained stable for 5years in majority of patients on ERT. However, in some patients they continued to decline in spite of ERT resulting in increased number of patients requiring ventilation and increase wheel chair dependence at the end of 5years.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alpha glucosidase deficiency; Enzyme replacement therapy; LOPD; Late-onset Pompe disease; Myozyme

Mesh:

Substances:

Year:  2016        PMID: 26873529     DOI: 10.1016/j.ymgme.2016.01.013

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  13 in total

1.  Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease.

Authors:  Jousef Alandy-Dy; Marie Wencel; Kathy Hall; Julie Simon; Yanjun Chen; Erik Valenti; Jade Yang; Deeksha Bali; Anita Lakatos; Namita Goyal; Tahseen Mozaffar; Virginia Kimonis
Journal:  Ann Transl Med       Date:  2019-07

2.  Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients.

Authors:  Jan C van der Meijden; Michelle E Kruijshaar; Dimitris Rizopoulos; Pieter A van Doorn; Nadine A M E van der Beek; Ans T van der Ploeg
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

3.  Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study.

Authors:  Sebastian Figueroa-Bonaparte; Jaume Llauger; Sonia Segovia; Izaskun Belmonte; Irene Pedrosa; Elena Montiel; Paula Montesinos; Javier Sánchez-González; Alicia Alonso-Jiménez; Eduard Gallardo; Isabel Illa; Jordi Díaz-Manera
Journal:  Sci Rep       Date:  2018-07-18       Impact factor: 4.379

4.  Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy.

Authors:  Hui-Yung Song; Chian-Shiu Chien; Aliaksandr A Yarmishyn; Shih-Jie Chou; Yi-Ping Yang; Mong-Lien Wang; Chien-Ying Wang; Hsin-Bang Leu; Wen-Chung Yu; Yuh-Lih Chang; Shih-Hwa Chiou
Journal:  Cells       Date:  2019-04-08       Impact factor: 6.600

5.  Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease.

Authors:  May Thandar Aung-Htut; Kristin A Ham; Michel Tchan; Russell Johnsen; Frederick J Schnell; Sue Fletcher; Steve D Wilton
Journal:  Sci Rep       Date:  2020-04-21       Impact factor: 4.379

6.  Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.

Authors:  Laurike Harlaar; Jean-Yves Hogrel; Barbara Perniconi; Michelle E Kruijshaar; Dimitris Rizopoulos; Nadjib Taouagh; Aurélie Canal; Esther Brusse; Pieter A van Doorn; Ans T van der Ploeg; Pascal Laforêt; Nadine A M E van der Beek
Journal:  Neurology       Date:  2019-10-16       Impact factor: 9.910

7.  Chest MRI to diagnose early diaphragmatic weakness in Pompe disease.

Authors:  Laurike Harlaar; Pierluigi Ciet; Gijs van Tulder; Alice Pittaro; Harmke A van Kooten; Nadine A M E van der Beek; Esther Brusse; Piotr A Wielopolski; Marleen de Bruijne; Ans T van der Ploeg; Harm A W M Tiddens; Pieter A van Doorn
Journal:  Orphanet J Rare Dis       Date:  2021-01-07       Impact factor: 4.123

8.  Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy.

Authors:  Jan C van der Meijden; Michelle E Kruijshaar; Laurike Harlaar; Dimitris Rizopoulos; Nadine A M E van der Beek; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2018-03-19       Impact factor: 4.982

9.  Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

Authors:  P Vanherpe; S Fieuws; A D'Hondt; C Bleyenheuft; P Demaerel; J De Bleecker; P Van den Bergh; J Baets; G Remiche; K Verhoeven; S Delstanche; M Toussaint; B Buyse; P Van Damme; C E Depuydt; K G Claeys
Journal:  Orphanet J Rare Dis       Date:  2020-04-05       Impact factor: 4.123

Review 10.  Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.

Authors:  Naresh K Meena; Nina Raben
Journal:  Biomolecules       Date:  2020-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.